Objectives: Postmastectomy radiotherapy (PMRT) is proven to decrease locoregional recurrence (LRR) in locally advanced breast cancer. However, there is little data regarding PMRT in early stage disease. This study examines risk factors for LRR in patients who underwent mastectomy for T1 N0 breast cancer, with the aim of identifying a subgroup who may potentially benefit from PMRT.
Methods: From 1994 to 2004, there were 1259 pathologic stage T1 N0 breast cancers treated with mastectomy and no radiation within the Kaiser Permanente Southern California medical system. Kaplan-Meier survival curves for LRR were compared using the log-rank test, and multivariate analysis was done using Cox proportional hazard ratios to identify risk factors for LRR.
Results: Median follow-up was 8.15 years. The 10-year Kaplan-Meier LRR rate was 3.2% (95% confidence interval [CI], 2%-4.3%). The median time to LRR was 2.5 years after mastectomy, and the most common site was chest wall (68%). Grade 3 (hazard ratio 3.97; 95% CI, 1.94-8.14; P = 0.0002) and margins ≤ 3 mm (hazard ratio 2.97; 95% CI, 1.21-7.29; P = 0.02) were significantly associated with LRR on multivariate analysis. The 10-year Kaplan-Meier rate of LRR for the 1230 patients with neither or one factor was 2.7% (95% CI, 1.6%-3.8%), compared with a LRR rate of 25% (95% CI, 2.2%-42.7%) among the 29 patients with both high grade and margins ≤ 3 mm (P < 0.0001).
Conclusions: After mastectomy for pT1 N0 breast cancer, there is a small subgroup of patients with grade 3 disease and a close or positive margin (≤ 3 mm) who have an increased risk of LRR. These patients may benefit from the administration of PMRT.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/COC.0b013e31827e54c2 | DOI Listing |
Front Biosci (Schol Ed)
December 2024
Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia.
Background: Breast cancer is a heterogeneous disease with distinct clinical subtypes, categorized by hormone receptor status, which exhibits different prognoses and requires personalized treatment approaches. These subtypes included luminal A and luminal B, which have different prognoses. Breast cancer development and progression involve many factors, including interferon-gamma ().
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
November 2024
Department of Breast Surgery, The First People's Hospital of Foshan, 528100 Foshan, Guangdong, China.
Objective: The current study aimed to develop an experimental approach for the direct co-culture of three-dimensional breast cancer cells using single-cell RNA sequencing (scRNA-seq).
Methods: The following four cell culture groups were established in the Matrigel matrix: the untreated Michigan Cancer Foundation (MCF)-7 cell culture group, the MCF-7 cell culture plus cisplatin group, the untreated co-culture group, and the cell co-culture plus cisplatin group. For cell co-culture, MCF-7 cells, human mammary fibroblasts, and human umbilical vein endothelial cells were mixed at a ratio of 1:1:1.
PPAR Res
December 2024
Department of Laboratory Medicine, The Sixth School of Clinical Medicine, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.
Triple-negative breast cancer (TNBC) is highly heterogeneous and poses a significant medical challenge due to limited treatment options and poor outcomes. Peroxisome proliferator-activated receptors (PPARs) play a crucial role in regulating metabolism and cell fate. While the association between PPAR signal and human cancers has been a topic of concern, its specific relationship with TNBC remains unclear.
View Article and Find Full Text PDFInt J Breast Cancer
December 2024
Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Previous studies have demonstrated that many healthcare workers in low- and middle-income countries (LMICs) lack the appropriate training and knowledge to recognize and diagnose breast cancer at an early stage. As a result, women in LMICs are frequently diagnosed with late-stage breast cancer (Stage III/IV) with a poor prognosis. We hosted a 1-day breast cancer educational conference directed towards healthcare workers in Honduras.
View Article and Find Full Text PDFOncol Res
December 2024
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Background: Triple-negative breast cancer (TNBC), characterized by its lack of traditional hormone receptors and HER2, presents a significant challenge in oncology due to its poor response to conventional therapies. Autophagy is an important process for maintaining cellular homeostasis, and there are currently autophagy biomarkers that play an effective role in the clinical treatment of tumors. In contrast to targeting protein activity, intervention with protein-protein interaction (PPI) can avoid unrelated crosstalk and regulate the autophagy process with minimal interference pathways.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!